Journal Article

Using human genetics to improve safety assessment of therapeutics

Diogo, Dorothée, Nelson, Matthew R, Carss, Keren J, Deaton, Aimee M, Del Rio-Espinola, Alberto, Fielden, Mark, Ward, Lucas D, Kulkarni, Diptee A, Yuan, Jing, Newham, Peter, Moggs, Jonathan, Sistare, Frank D

2023

Overview

Human genetics research has discovered thousands of proteins associated with complex and rare diseases. Genome-wide association studies (GWAS) and studies of Mendelian disease have resulted in an increased understanding of the role of gene function and regulation in human conditions. Although the application of human genetics has been explored primarily as a method to identify potential drug targets and support their relevance to disease in humans, there is increasing interest in using genetic data to identify potential safety liabilities of modulating a given target. Human genetic variants can be used as a model to anticipate the effect of lifelong modulation of therapeutic targets and identify the potential risk for on-target adverse events. This approach is particularly useful for non-clinical safety evaluation of novel therapeutics that lack pharmacologically relevant animal models and can contribute to the intrinsic safety profile of a drug target. This Review illustrates applications of human genetics to safety studies during drug discovery and development, including assessing the potential for on- and off-target associated adverse events, carcinogenicity risk assessment, and guiding translational safety study designs and monitoring strategies. A summary of available human genetic resources and recommended best practices is provided. The challenges and future perspectives of translating human genetic information to identify risks for potential drug effects in preclinical and clinical development are discussed.Studies of human genetics have been used to identify promising drug targets, and might also inform safety assessment in the drug discovery process. In their Review, Ward and co-authors from industry discuss how genetic studies of rare and complex human diseases can be used to predict potential on- and off-target effects associated with modulating a given target. They also outline suggested best practices for incorporating human genetic data into safety assessments during drug development.

• Publisher: Nature Publishing Group
• Subject: Clinical trials / Drug development / Drugs / Genetic engineering / Genomes / Genotype & phenotype / Pharmacovigilance / Product safety / R&D / Rare diseases / Research & development